small molecule

CRESEMBA

ISAVUCONAZONIUM SULFATE

Loss of exclusivityJune 2031FDA regulatory exclusivity expiry

CompanyAstellas Pharma Us →See this company's full patent-cliff portfolio

Drug detail

Brand name	CRESEMBA
Active ingredient	ISAVUCONAZONIUM SULFATE
Strength	372MG
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	March 2015
Marketing status	RX

Listed patents

Patent	Expires	Type
6812238*PED	April 2026	—
6812238	October 2025	substance

Regulatory exclusivity

Code	Expires
PED	June 2031
ODE-453	December 2030
ODE-459	December 2030
GAIN	September 2027
PED	June 2027
NPP	December 2026
PED	September 2022
ODE-90	March 2022
ODE-305	March 2022

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Astellas Pharma Us